Suppr超能文献

非甾体抗炎药与线粒体氧化磷酸化解偶联

Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation.

作者信息

Mahmud T, Rafi S S, Scott D L, Wrigglesworth J M, Bjarnason I

机构信息

King's College Hospital, London, UK.

出版信息

Arthritis Rheum. 1996 Dec;39(12):1998-2003. doi: 10.1002/art.1780391208.

Abstract

OBJECTIVE

There is a lack of correlation between cyclooxygenase (COX) inhibition and nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal (GI) damage; it has been suggested that mucosal damage may be initiated by a "topical" action of NSAIDs involving mitochondrial injury. We evaluated the effect of a range of NSAIDs and related compounds on mitochondrial function and assessed the differences between them in relation to their physicochemical properties.

METHODS

Stimulation of respiration, as an indicator of mitochondrial uncoupling, was measured in isolated coupled rat liver mitochondrial preparations, using an oxygen electrode.

RESULTS

Conventional NSAIDs and acidic prodrugs all had stimulatory effects on mitochondrial respiration at micromolar concentrations (0.02-2.7 microM); higher concentrations were inhibitory. The uncoupling potency was inversely correlated with drug pKa (r = -0.87, P < 0.001; n = 12). Drugs known to have good GI tolerability, including modified flurbiprofen (dimero-flurbiprofen and nitrobutyl-flurbiprofen), nabumetone (a non-acidic prodrug), and non-acidic highly selective COX-2 inhibitors, did not cause uncoupling.

CONCLUSION

The ability to uncouple mitochondrial oxidative phosphorylation is a common characteristic of antiinflammatory agents with an ionizable group. Modification or absence of an ionizable moiety reduces the effect on mitochondria and could lead to improved NSAID GI safety.

摘要

目的

环氧化酶(COX)抑制作用与非甾体抗炎药(NSAID)引起的胃肠道(GI)损伤之间缺乏相关性;有人提出,黏膜损伤可能由NSAIDs的“局部”作用引发,涉及线粒体损伤。我们评估了一系列NSAIDs及相关化合物对线粒体功能的影响,并根据其理化性质评估了它们之间的差异。

方法

使用氧电极在分离的偶联大鼠肝线粒体制剂中测量呼吸刺激,作为线粒体解偶联的指标。

结果

传统NSAIDs和酸性前药在微摩尔浓度(0.02 - 2.7 microM)下均对线粒体呼吸有刺激作用;较高浓度则具有抑制作用。解偶联能力与药物pKa呈负相关(r = -0.87,P < 0.001;n = 12)。已知具有良好胃肠道耐受性的药物,包括改良氟比洛芬(二聚体氟比洛芬和硝基丁基氟比洛芬)、萘丁美酮(一种非酸性前药)和非酸性高选择性COX - 2抑制剂,不会引起解偶联。

结论

使线粒体氧化磷酸化解偶联的能力是具有可电离基团的抗炎药的共同特征。可电离部分的修饰或缺失会降低对线粒体的影响,并可能改善NSAID的胃肠道安全性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验